Green Cross’s Hepabig-Gene gets orphan drug designation

Published: 2013-05-21 06:56:00

Updated: 2013-05-21 06:56:00

Green Cross Corp. said last Thursday that Hepabig-Gene, a recombinant antibody for hepatitis B, was designated as an “orphan drug” by the United States Food and Drug Administration (FDA).

The FDA provides orphan drug designation to drugs that seek to treat rare diseases or conditions for which...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK